The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Efavirenz/Emtricitabine/Tenofovir Disoproxil Clonmel 600 mg/200 mg/245 mg film-coated tablets

Clonmel Healthcare LtdPA0126/301/001

Main Information

Trade NameEfavirenz/Emtricitabine/Tenofovir Disoproxil Clonmel 600 mg/200 mg/245 mg film-coated tablets
Active SubstancesEfavirenz
Tenofovir disoproxil
Dosage FormFilm-coated tablet
Licence HolderClonmel Healthcare Ltd
Licence NumberPA0126/301/001

Group Information

ATC CodeJ05AR Antivirals for treatment of HIV infections, combinations
J05AR06 emtricitabine, tenofovir disoproxil and efavirenz


License statusAuthorised
Licence Issued22/12/2017
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back